文献速递重症综合管理与镇静镇痛

氟哌啶醇与可乐定及谵妄缓解:危重症患者的前瞻性队列研究

Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study.
PubMed 文献 · Intensive Care Med · 2021-02-16
一句话结论在谵妄ICU患者中,使用氟哌啶醇、可乐定或二者联合与谵妄缓解概率降低相关(OR 0.47、0.78、0.45),作者认为需进一步研究。

该前瞻性队列研究纳入混合ICU患者3614例(谵妄1165例,32%;非谵妄2449例,68%),排除原发神经系统疾病患者,采用倾向性评分匹配和马尔可夫多项逻辑回归模型分析每日转换。结果显示,与未治疗的谵妄患者相比,接受氟哌啶醇(OR 0.47,95%CI 0.39-0.57)、可乐定(OR 0.78,95%CI 0.63-0.97)或二者联合(OR 0.45,95%CI 0.36-0.56)的谵妄患者谵妄缓解概率更低。这些患者谵妄持续时间更长、谵妄天数及机械通气天数更多、ICU及住院时间更长,但对ICU死亡率无影响。作者认为该发现受观察性分析固有局限性的限制,值得进一步研究。

要点

  • 与未治疗的谵妄患者相比,接受氟哌啶醇的谵妄患者谵妄缓解概率更低(OR 0.47,95%CI 0.39-0.57)。
  • 与未治疗的谵妄患者相比,接受可乐定的谵妄患者谵妄缓解概率更低(OR 0.78,95%CI 0.63-0.97)。
  • 与未治疗的谵妄患者相比,接受氟哌啶醇与可乐定联合治疗的谵妄患者谵妄缓解概率更低(OR 0.45,95%CI 0.36-0.56)。
  • 接受氟哌啶醇、可乐定或二者联合的谵妄患者,谵妄持续时间更长、谵妄天数及机械通气天数更多、ICU及住院时间更长。
  • 这些药物对ICU死亡率无影响;作者认为该发现值得进一步研究。

适用人群与场景

  • 混合ICU患者,排除原发神经系统疾病患者。
  • 共纳入3614例患者,其中谵妄1165例(32%),非谵妄2449例(68%)。

研究设计与关键结果

  • 研究类型为前瞻性队列研究,纳入混合ICU患者3614例(谵妄1165例,32%;非谵妄2449例,68%),排除原发神经系统疾病患者。
  • 谵妄发生于24,906天中的4708天(18.9%)。
  • 与未治疗的谵妄患者相比,接受氟哌啶醇的谵妄患者谵妄缓解概率更低(OR 0.47,95%CI 0.39-0.57)。
  • 与未治疗的谵妄患者相比,接受可乐定的谵妄患者谵妄缓解概率更低(OR 0.78,95%CI 0.63-0.97)。
  • 与未治疗的谵妄患者相比,接受氟哌啶醇与可乐定联合治疗的谵妄患者谵妄缓解概率更低(OR 0.45,95%CI 0.36-0.56)。
  • 接受氟哌啶醇、可乐定或二者联合的谵妄患者,谵妄持续时间更长、谵妄天数及机械通气天数更多、ICU及住院时间更长。
  • 这些药物对ICU死亡率无影响。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 采用倾向性评分匹配和马尔可夫多项逻辑回归模型分析每日转换。
  • 局限:作者指出该发现受观察性分析固有局限性的限制,值得进一步研究。

对床旁实践的改变

  • 作者认为,在谵妄ICU患者中使用氟哌啶醇和可乐定可能与谵妄缓解概率降低相关,但该发现值得进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium. The objective of this study was to determine whether haloperidol, clonidine, or their combined administration to delirious ICU patients results in delirium resolution.

METHODS: This was a cohort study on a mixed ICU, excluding patients with a primary neurological disorder. The main outcome was the probability of delirium resolution, using propensity score matching and Markov multinomial logistic regression models for daily transitions. Secondary outcomes were delirium duration, number of delirium days, ventilation days, length of stay in the ICU and hospital, and ICU mortality.

RESULTS: A total of 3614 patients were included (1165 delirious [32%]; 2449 non-delirious [68%]). Delirium occurred on 4708 (18.9%) of 24,906 days. The probability of delirium resolution was lower in delirious patients who received haloperidol (OR 0.47, 95% CI 0.39-0.57), clonidine (OR 0.78, 95% CI 0.63-0.97), or both (OR 0.45, 95% CI 0.36-0.56) compared to untreated delirious patients. Delirious patients who received haloperidol, clonidine, or both had generally longer delirium duration, more delirium and ventilation days, and spent more time in the ICU and in hospital than untreated delirious patients. These agents had no effect on ICU mortality.

CONCLUSION: Haloperidol and clonidine use in delirious ICU patients may be associated with reduced probability of delirium resolution. This finding, however, merits further investigation given inherent limitations of this observational analysis.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Smit L, Dijkstra-Kersten SMA, Zaal IJ, et al. Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. Intensive Care Med. 2021. PMID: 33591422. doi:10.1007/s00134-021-06355-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。